04006nam a22005895i 4500 978-981-97-3446-7 DE-He213 20251030112708.0 cr nn 008mamaa 240802s2024 si | s |||| 0|eng d 9789819734467 978-981-97-3446-7 10.1007/978-981-97-3446-7 doi RC705-779 MJL bicssc MED079000 bisacsh MJL thema Gemma, Akihiko. author. aut http://id.loc.gov/vocabulary/relators/aut 81839 Analysis File of Drug-Induced Lung Injury [electronic resource] : Expert Opinion for Analysis of Big Data / by Akihiko Gemma. 1st ed. 2024. Singapore : Springer Nature Singapore : Imprint: Springer, 2024. XII, 116 p. 48 illus., 18 illus. in color. online resource. text txt rdacontent computer c rdamedia online resource cr rdacarrier text file PDF rda Part I Understanding Drug-Induced Lung Injuries -- 1 Understanding Drug-Induced Lung Injuries -- Part 2 Actual Practice in Drug-Induced Lung Injuries of Each Drug -- 2 EGFR inhibitors (gefitinib, erlotinib, afatinib, osimertinib) -- 3 Anti-EGFR antibodies (cetuximab, panitumumab, necitumumab) -- 4 mTOR inhibitors (temsirolimus, everolimus) -- 5 Proteasome inhibitor (bortezomib) -- 6 Immune checkpoint inhibitors (nivolumab, pembrolizumab, atezolizumab, durvalumab) -- 7 Neoangiogenesis inhibitors (sunitinib, sorafenib, bevacizumab) -- 8 Other molecular targeted drugs (crizotinib, alectinib, etc.) -- 9 Antibody-drug conjugates (ADC) (trastuzumab emtansine, trastuzumab deruxtecan) -- 10 Anti-cancer drugs (TS-1, taxanes, CPT-11, platinum-containing drugs, etc.). This book describes the pathologic conditions of drug-induced lung injuries, monitoring strategies, and guides on how to interpret the evidence. It also dives into particular drugs that caused the disorder, such as EGFR inhibitors, anti-EGFR antibodies, mTOR inhibitors, proteasome inhibitors, immune checkpoint inhibitors, neoangiogenesis inhibitors, and other molecular targeted drugs. It outlines the analysis and interpretation of the post-marketing survey on surveillance of each drug for inducing pulmonary lesions presenting diffuse haziness. The data and analysis from this survey are valuable since a guideline is yet to be established due to limited clinical evidence and cases. As new drugs are developed, establishing treatment and event management is crucial. Thus, Drug-induced Pulmonary Disorder in Medical Oncology - Expert Opinion to Decipher Big Data summarizes the accumulated information to provide a foundation for further research advancement. The book offers a refreshing alternative to current approaches to medical oncology and respiratory diseases professionals and will also attract medical affairs members in global pharmaceutical companies. Respiratory organs Diseases. 77494 Medical genetics. 64976 Diseases Causes and theories of causation. 78871 Oncology. 70760 Pharmacology. 67844 Genetics Research. 79924 Pneumology. 77495 Clinical Genetics. 73305 Pathogenesis. 78872 Oncology. 70760 Pharmacology. 67844 Genetics Research. 79925 SpringerLink (Online service) Springer Nature eBook Printed edition: 9789819734450 Printed edition: 9789819734474 Printed edition: 9789819734481 https://doi.org/10.1007/978-981-97-3446-7 ZDB-2-SME ZDB-2-SXM 62199 62199